Multiple unbiased approaches identify oxidosqualene cyclase as the molecular target of a promising anti-leishmanial

Search results

• Finished

  Wellcome Centre for Anti-Infectives Research

  Cook, S. (Investigator), De Rycker, M. (Investigator), Fairlamb, A. (Investigator), Ferguson, M. (Investigator), Field, M. (Investigator), Gilbert, I. (Investigator), Gray, D. (Investigator), Horn, D. (Investigator), Pawlowic, M. C. (Investigator), Read, K. (Investigator), Wyatt, P. (Investigator) & Wyllie, S. (Investigator)

  1/04/17 → 31/03/25

  Project: Research

  • Drug Discovery 100%
  • Trypanosoma Cruzi (T. cruzi) 92%
  • Chagas Disease 68%
  • Visceral Leishmaniasis 66%
  • Trypanosoma Cruzi 65%

• Chemical Biology: Leveraging Phenotypic Hits Against Kinetoplastids (Strategic Grant)

  Fairlamb, A. (Investigator), Field, M. (Investigator), Gilbert, I. (Investigator), Gray, D. (Investigator), Horn, D. (Investigator) & Wyatt, P. (Investigator)

  1/01/15 → 31/12/20

  Project: Research

  • Visceral Leishmaniasis 100%
  • Drug Discovery 96%
  • Leishmania Donovani 82%
  • Chagas Disease 74%
  • Drug Target 69%

• Protein Glycosylation in Trypanosomes: Defining and Exploiting a Biological System (Senior Investigator Award)

  Ferguson, M. (Investigator)

  1/10/13 → 30/06/23

  Project: Research

  • Trypanosoma Brucei 100%
  • GPI-anchored Protein (GPI-AP) 40%
  • Bloodstream Forms 37%
  • T. Brucei 35%
  • Trypanosoma 33%